AN UPDATED REVIEW OF STEALTH LIPOSOMES AND ITS ABILITY TO EVADE THE IMMUNE SYSTEM: A NEW FRONTIER IN CANCER CHEMOTHERAPY

DURGARAMANI SIVADASAN*

Department of Pharmaceutics, College of Pharmacy, Jazan University, Jazan, Saudi Arabia
*Corresponding author: Durgaramani Sivadasan; Email: dsivadasa@jazanu.edu.sa

Received: 13 Feb 2024, Revised and Accepted: 21 Mar 2024

ABSTRACT

Liposomes have been the delivery of choice for the cancer targeting therapy for the last few decades. Since the 1990s, the development of sterically stabilized (stealth) liposomes has garnered interest for their long circulating half-life. PEGylated (Polyethylene Glycol) liposomes are most extensively studied for delivering cancer therapeutics in a sustained manner. Stealth liposomes are having a less intrinsic toxicity with higher efficacy in cancer treatment. There are numerous clinical trials on the liposomes in tackling cancer is evident for the better outcome of the delivery system. Stealth liposomes are extensively studied for their improved circulation time and better pharmacokinetic profile in cancer treatment. The steric hindrance of the stealth liposomes bypasses the reticuloendothelial system clearance. Further the ligands conjugation in the surface of the liposomes able to achieve better target to the cancer cells. The vascularization nature of the cancerous cells is readily making the liposomal delivery of the cancer drugs accumulate in the cancerous cells rather than healthy cells. There is an utmost need to understand the possible mechanism of stealth liposomes and the basic science behind the development of liposomal delivery system in advancing the cancer treatment with less toxicity. The present review addresses the various modalities of the liposomal development, liposome characterization, mechanism of PEGylated liposomes, the advancements and results of the liposomes in the treatment of various diseases, and the clinical trials and regulatory considerations of liposomal drug delivery system.

Keywords: Liposomes, Stealth liposomes, Cancer, PEGylation, Targeted delivery, Enhanced permeation and retention effect

INTRODUCTION

There are various drug delivery techniques adopted for delivering cancer therapeutics for effective treatment outcomes. In this line, various drugs, vaccines, enzymes, proteins, and genetic materials are delivered in sustained action forms using conventional liposomes, which are microscopic in nature. The liposomes contain the molecular “payload,” which eventually degrades spontaneously and releases its contents into the bloodstream or tissues by diffusing via capillary walls. When conventional liposomes are used for treatment, several drawbacks have been documented, including blood clearance, limited specificity, phagocytosis, opsonization low binding site, low bioavailability, low retention, and low effectiveness. The rapid Monomacrophage Phagocyte System (MPS) absorption of typical liposomes upon systemic injection is a significant disadvantage. Therefore, new liposome generations known as stealth liposomes were developed to overcome the demerits of conventional liposomal delivery systems.

Stealth liposomes and immuno-liposomes are avoid being detected by the immune system. Conventional liposomes, particularly ones that are injected into the body, are not stable for extended periods of time. Stealth liposomes are sterically stabilized, gained attention for its long circulating half-life. PEGylated liposomes are more extensively studied for its potential effect in delivering cancer therapeutics [1-4].

Conventional and stealth liposomes

The conventional liposomes are the first generation of liposomes created from phospholipids, either natural or synthetic, with or without cholesterol [5]. Cholesterol was incorporated to dipalmitoyl phosphatidylcholine (DPPC) liposome membrane permeability and fluidity which reduces the rigidity of the liposomal membrane bilayer and the stability of the liposomes composed of Distearoylphosphatidylcholine (DSPC) [6, 7]. Moreover, rigid liposomes exhibit better tumor penetration and enhanced anti-tumor efficacy [8]. Dipalmitoyl phosphatidylcholine (DPPC) liposome membrane permeability and fluidity are both influenced by cholesterol levels. Elevated cholesterol levels led to a rise in the size of typical liposomes and a change in their morphology from amorphous to nanosized, regular, and spherical vesicles. Further, cholesterol affects the release of hydrophilic molecules from lipid vesicles and reduced the fluidity of the bilayer [9].

Reports clarified that a stable liposome has to include the appropriate amount of membrane fluidity and cholesterol (about 50 mol %) [10]. As a result, cholesterol is essential for the fluidity and rigidity of the liposome bilayer. Nevertheless, these properties are impacted by the cholesterol to phospholipid molar ratio, the specific phospholipids utilized, and the type of drug being encapsulated. Upon administration, conventional liposomes go to the site of action via systemic circulation. Owing to their tiny size in microns, they passively diffuse through the blood vessel’s permeable walls and reach the tumour region. Conventional liposomes can pass through cancer cells yet lack the appropriate retention action since the outer surface does not have a binding mechanism.

Conventional liposomes have been shown to be ineffective in treating tumour cells due to their short blood circulation time and its inability to bind to the tumor sites, the mononuclear phagocyte system quickly eliminates them and they rapidly accumulate up in the liver and spleen [11]. Hence, MPS prevents conventional liposomes from reaching the target area and limits their dissemination to other tissues and reticuloendothelial system (RES), makes them susceptible to phagocytosis induced degradation or deactivation. The conventional liposomes showed only a moderate degree of stability in an in vitro environment and to improve in vivo liposome stability and blood circulation, stealth (sterically stabilized) liposomes were developed [12].

Over the past few decades, various hypothesis have been proposed to understand the pharmacokinetic properties of two nanoscale systems for drug delivery, polymeric nanoparticles and liposomes. In conventional liposome, opsonization facilitates the phagocytosis process by utilizing Vander Waals, electrostatic, ionic and hydrophobic/hydrophilic forces to interact with nanoparticles in the circulation. Therefore, the nano carriers surface characteristics are crucial to the opsonization process. Hydrophobic and charged particles are more opsonized than hydrophilic and neutrally charged particles. Surfaces can be coated with hydrophilic polymers to produce stealth systems to prevent the opsonization process.
The early 1990s witnessed the culmination of this liposome engineering process with the identification that encapsulating liposomes with PEG, a synthetic hydrophilic polymer. The most effective technique for creating "stealth" masks was liposomal surface modification utilizing polyacrylamide, polyvinyl alcohol, polycarbohydrates, and PEG and its co-polymers [13-15]. PEGylation is the process of using PEG as a polymer. Stealth liposomes drug delivery system are spherical, phospholipid bilayer membrane coated vesicles utilized to carry genetic material or drugs into cells and able to escape the detection by the mononuclear phagocyte system [16]. PEG exists on the surface of liposomes, which limits MPS absorption, reduces renal clearance rate and prolongs circulation time by enhancing bioavailability and preventing MPS from binding to opsonins. Strong inter bilayer repulsion produced by the PEG coated liposomes enables them to resist attractive van der Waals forces, preventing aggregation and stabilizing liposomes [17, 18].

Sterically stabilized or stealth liposomes are other identities for these PEG coated liposomes. The several blood components interact hydrophobically and electrostatically with highly concentrated regional groups at the liposome surface, which causes the PEG stabilizing action. It has been shown that stealth liposomes differ from conventional liposomes in their dose independent pharmacokinetics [19, 20]. The highly effective intravenous injectable drug Doxil®, used as a remedy to treat advanced ovarian cancer, multiple myeloma, and human immunodeficiency virus (HIV) associated Kaposi’s sarcoma, was developed using this technique [21]. The stealth liposome technology has made considerable progress, and several important formulations for the treatment of different diseases are now available commercially or in advanced clinical trials (table 1).

Publications from various sources (pubmed, ScienceDirect, google scholar; years of use: 2000-2024 and the key words used are liposomes, stealth liposomes, cancer, PEGylation, targeted delivery) are noted with emphasis on methods of preparation, characterization and recent advances of stealth liposomes. A detailed analysis is also given to commercially available conventional and stealth liposomal compositions and their applications. Further, ongoing research on clinical trials and patents sanctioned in recent past is well detailed. To support this topic, the most pertinent literature from recent studies has been compiled. In order to pave the way for liposomes from manufacture to clinical use, this review article can provide up-to-date knowledge on a variety of uses along with an idea on current research in clinical trials and patents.

Table 1: List of stealth liposomes under clinical trials

<table>
<thead>
<tr>
<th>Trail/identifier number</th>
<th>Study</th>
<th>Status</th>
<th>Phase</th>
<th>Study completion date</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03983996</td>
<td>PEGylated liposomal doxorubicin or epirubicin in neoadjuvant or adjuvant chemotherapy for breast cancer</td>
<td>Completed</td>
<td>Not applicable</td>
<td>May 1, 2020</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03033316</td>
<td>An evaluation of the safety of oncort IV PEGylated liposomal decamethasone phosphate in patients with progressive multiple myeloma (AMETHYST)</td>
<td>Terminated</td>
<td>(Patient enrolment issues)</td>
<td>August 2020</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT01379989</td>
<td>Innovatyon study-international, randomized study in patients with ovarian cancer (INOVATYON)</td>
<td>Completed</td>
<td>Phase 3</td>
<td>December 17, 2020</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT01837251</td>
<td>Evaluation of optimal treatment with bevacizumab in patients with platinum sensitive recurrent ovarian cancer</td>
<td>Completed</td>
<td>Phase 3</td>
<td>January 2021</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT02606305</td>
<td>Study of nirvexumab soravane in combination with bevacizumab, carboplatin, PEGylated liposomal doxorubicin, pembroizumab, or bevacizumab+carboplatin in participants with folate receptor alpha (FRA) positive advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer</td>
<td>Completed</td>
<td>Phase 1</td>
<td>March 12, 2021</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03719326</td>
<td>A study to evaluate safety/tolerability of immunotherapy combinations in participants with triple-negative breast cancer or gynecologic malignancies</td>
<td>Completed</td>
<td>Phase 1</td>
<td>July 2, 2021</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT02865811</td>
<td>Pembrolizumab combined with PEGylated liposomal doxorubicin (PLD) for recurrent platinum resistant ovarian, fallopian tube or peritoneal cancer</td>
<td>Completed</td>
<td>Phase 2</td>
<td>March 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04592692</td>
<td>A pharmacokinetic and clotting activity study of FYVIII-PEGylated liposomes</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>May 31, 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03470808</td>
<td>Olaparib after response to trabectin in PEGylated liposomal doxorubicin in recurrent ovarian carcinoma</td>
<td>Completed</td>
<td>Phase 2</td>
<td>July 27, 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT01210768</td>
<td>A study of PEGylated liposomal doxorubicin and cyclophosphamide in human epidermal growth factor receptor 2 (Her2) negative stage I and II breast cancer patients</td>
<td>Active, not recruiting</td>
<td>Phase 2</td>
<td>October 31, 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03971926</td>
<td>Metronomic PLD in patients with primary endocrine resistant advanced breast cancer</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>December 1, 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03161132</td>
<td>Resistant ovarian cancer, olaparib and liposomal doxorubicin (ROLANDO)</td>
<td>Completed</td>
<td>Phase 2</td>
<td>December 31, 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT01990352</td>
<td>Correlate BRCA1 protein expression with response to DNA damaging chemotherapy</td>
<td>Completed</td>
<td>Phase 2</td>
<td>December 31, 2022</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03952572</td>
<td>Efficacy and safety of CDOP (PEGylated liposomal doxorubicin, vincristine and prednisone) vs CHOP (cyclophosphamide-hydroxy daunorubicin-oncovicin-prednisone) for newly diagnosed peripheral T-cell lymphoma</td>
<td>Recruiting</td>
<td>Phase 3</td>
<td>April 30, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT03596281</td>
<td>Pembrolizumab in combination with bevacizumab and PEGylated liposomal doxorubicin in patients with ovarian cancer (PEMBOV)</td>
<td>Active, not recruiting</td>
<td>Phase 1</td>
<td>April 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT02456857</td>
<td>Liposomal doxorubicin, bevacizumab, and everolimus</td>
<td>Active, not recruiting</td>
<td>Phase 2</td>
<td>May 24, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>Trail/identifier number</td>
<td>Study</td>
<td>Status</td>
<td>Phase</td>
<td>Study completion date</td>
<td>References</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-------</td>
<td>--------------</td>
<td>-------</td>
<td>-----------------------</td>
<td>------------</td>
</tr>
<tr>
<td>NCT03907475</td>
<td>Locally advanced malignant solid neoplasm metastatic cancer: a moonshot initiative</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>June 1, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT0657878</td>
<td>Efficacy study of chemotherapy to treat ovarian cancer</td>
<td>Active, not recruiting</td>
<td>Phase 3</td>
<td>July 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT02312245</td>
<td>Recurrent fallopian tube carcinoma: recurrent ovarian carcinoma</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>July 15, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04092270</td>
<td>A study combining the peposertib (M3814) pill with standard chemotherapy</td>
<td>Recruiting</td>
<td>Phase 1</td>
<td>September 1, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04092270</td>
<td>A study combining the peposertib (M3814) pill with standard chemotherapy in patients with ovarian cancer with an expansion in high grade serous ovarian cancer and low grade serous ovarian cancer</td>
<td>Recruiting</td>
<td>Phase 1</td>
<td>September 1, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT02446600</td>
<td>Testing the use of a single drug (olaparib) or the combination of two drugs (cediranib and olaparib) compared to the usual chemotherapy for women with platinum sensitive ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>Active, not recruiting</td>
<td>Phase 3</td>
<td>December 30, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05346107</td>
<td>PLD-cyclophosphamide-Nab-P continuously combined with dual HER2 blockade for HER2-positive breast cancer</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>December 31, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04274426</td>
<td>Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer (MIRASOL)</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>December 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT01970722</td>
<td>Surgery and chemotherapy with or without chemotherapy after surgery in treating patients with ovarian, fallopian tube, uterine, or peritoneal cancer</td>
<td>Active, not recruiting</td>
<td>Phase 1</td>
<td>December 22, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT01802749</td>
<td>Bevacizumab beyond progression in platinum sensitive ovarian cancer (MITO16MANG02b)</td>
<td>Active, not recruiting</td>
<td>Phase 3</td>
<td>December 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04209855</td>
<td>A study of mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression (MIRASOL)</td>
<td>Active, not recruiting</td>
<td>Phase 3</td>
<td>April 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT02839707</td>
<td>PEGylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab in treating patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer</td>
<td>Active, not recruiting</td>
<td>Phase 2/Phase 3</td>
<td>June 30, 2024</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04077275</td>
<td>ATG-010 (selenoxor) in combination with chemotherapy in relapsed/refractory multiple myeloma (RRMM)</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>December 30, 2024</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04729387</td>
<td>Alpelisib plus olaparib in platinum resistant/refractory, high grade serous ovarian cancer, with no germline breast cancer gene (BRCA) mutation detected</td>
<td>Recruiting</td>
<td>Phase 3</td>
<td>January 31, 2025</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04244552</td>
<td>A phase 1b trial of anti-ribonucleoprotein antibody (ATRC-101) in adults with advanced solid malignancies</td>
<td>Recruiting</td>
<td>Phase 1</td>
<td>March 2025</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05386524</td>
<td>Sintilimab and bevacizumab biosimilar combined with PLD in metastatic triple negative breast cancer (mTNBC)</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>March 15, 2025</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT04814875</td>
<td>A study to evaluate the combination of ATX-101 and platinum based chemotherapy</td>
<td>Recruiting</td>
<td>Phase 1</td>
<td>March 31, 2025</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05483933</td>
<td>Phase 1b study of SL-172154 administered with combination agent(s) in subjects with ovarian cancers</td>
<td>Recruiting</td>
<td>Phase 1</td>
<td>April 2025</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05711615</td>
<td>Testing low-dose common chemotherapy (liposomal doxorubicin) in combination with an anticancer drug, peposertib, in advanced sarcoma</td>
<td>Not yet recruiting</td>
<td>Phase 1</td>
<td>May 3, 2025</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05656079</td>
<td>To evaluate the cardiac safety of PEGylated liposomal doxorubicin concurrently plus trastuzumab and pertuzumab in the adjuvant setting for early-stage HER-2-positive breast cancer: a multicenter, randomized controlled clinical study</td>
<td>Recruiting</td>
<td>Not applicable</td>
<td>September 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05388487</td>
<td>Tolerability and safety of HF1K16 (investigational PEGylated liposome formulation of All-Trans Retinoic Acid) injection in patients with refractory solid tumors</td>
<td>Recruiting</td>
<td>Phase 1</td>
<td>November 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05261490</td>
<td>Study of maplirpacept (PF-07901801) in combination with PLD in patients with platinum resistant ovarian cancer</td>
<td>Recruiting</td>
<td>Phase 2</td>
<td>December 4, 2023</td>
<td>[22-30]</td>
</tr>
<tr>
<td>NCT05684731</td>
<td>Safety and efficacy of KM1 (injection of polyphase liposome-encapsulated cisplatin) in subjects with</td>
<td>Not yet recruiting</td>
<td></td>
<td>June 1, 2026</td>
<td>[22-30]</td>
</tr>
</tbody>
</table>
Characteristics of stealth liposomes

The structure and composition of the stealth liposome are identical to those of the host cell and consist of cholesterol and phospholipids like phosphatidylycholine or diacetylphosphate [31]. The phospholipid bilayer is made up of a hydrophilic head portion, a hydrophobic tail and an outer coat made of PEG or another type of polymer. In nature, stealth liposomes are stable. A stealth liposome’s size and form might vary depending on the substance and material utilized. They delay the release of drugs, as the endoplasmic reticulum cannot absorb them. They range from 50 to 200 nm in size. Phospholipids and spingolipids, glycolipids, and sterols are the most frequently used lipids.

The uniform, colloidal stealth liposomes have a colloidal structure (fig. 1). These spheres, also known as stealth liposomes, are tiny deposits that can be designed to retain a gene for gene therapy, an antibiotic, an allergen, an antigen, or both. The stealth liposome is uniform and colloidal in structure. Drugs that are both hydrophilic and lipophilic can be administered via the liposome without any chemical modification.

Fig. 1: Structure of a stealth liposome (Created by BioRender.com)

Structure of a stealth liposome

PEG has been extensively utilized as the polymeric stearic stabilizer over the numerous polymers assessed to accelerate the blood circulation period of liposomes. Although there are other ways to incorporate it into the liposomal surface, the most popular technique now is to anchor the polymer in the liposomal membrane using a cross-linked lipid, such as PEG distearyl phosphatidylethanolamine [DSPE] (fig. 2).

Formulation modalities

There are various preparations methods established for the liposomal formulation development [32-38]. The same techniques are utilized to produce stealth liposomes. However, PEGylation is a crucial step that must be included in these techniques for the design of stealth liposomes. The process of enabling polymer to encapsulate a liposome is known as PEGylation (fig. 3).
Mechanism-stealth liposome transportation

Numerous mechanisms exist for liposomes to interact with cells viz., phagocytic reticuloendothelial system cells like neutrophils, macrophages and endocytose. Weaker electrostatic or hydrophobic forces that are generally present and/or particular interactions with cell surface components may induce adsorption on the cell surface. By embedding the liposome's lipid bilayer into the plasma membrane and simultaneously releasing its contents into the cytoplasm, the liposome is able to fuse with the plasma cell membrane. Without any direct association to the liposomes contents, lipids from liposomes are transferred to cellular or subcellular membranes or vice versa. When multiple mechanisms are involved, it can be challenging to distinguish which one is in use [39].

PEGylation

There are two techniques for PEGylation: the pre-insertion technique, which involves adding PEG-lipids to the lipid composition and the post-insertion technique, which combines PEG-lipids with liposomal
dispersion before the formation of the liposomes. The efficiency of liposomal PEGylation depends on the length and density of PEG. The extremely long PEG chains significantly reduce the transfection activity and the very small PEG molecules neither restrict protein absorption nor increase blood circulation. Typically, medium-length PEG molecules are employed to modify liposomes. The covering density increases as the molar PEG-lipid/lipid composition ratio increases. PEG concentrations of 5% or less develop a mushroom-like shape, 5%-15% PEG forms a mushroom or brush-like shape with 100% coverage and >15% PEG gives a brush-like shape with 100% coverage (fig. 4).

By inhibiting MPS absorption, or the interaction between liposomes and macrophages, PEGylation prolongs the duration of circulation [40, 41]. Additionally, PEG liposomes are known to accumulate in tumour foci. The steric barrier and blood protein binding mediate the interaction between PEG liposomes and macrophages. Prolonged circulation periods and more stable steric barriers are frequently found in liposomes with a brush-like covering (fig. 5) [42].

Pre-insertion PEGylation

Traditionally, the pre-insertion approach is used to develop PEGylated liposomes. Sonication is used to hydrate thin lipid films, resulting in the formation of liposomal particles [43]. Lipids bearing PEGs at their head groups are mixed with cationic, anionic, or neutral lipids on the thin film stage [44-46]. For liposomal PEGylation, the most prevalent phosphatidylethanolamines (PE) are DSPE-mPEG, DPPE-mPEG, and DOPE-mPEG, which vary in the hydrophobic domain, PEG chain length and fatty acid type [47-49].

The most effective PEG compounds for stabilizing liposomal structures in the circulation were found to have a 2000 Da molecular mass. In vivo tests revealed that PEG2000 modified liposomes are four times as efficient at targeting tumour tissue than conventional liposomes [50]. Utilizing defined sequence PEGs is now feasible due to the latest advances in polymer synthesis (liquid phase iterative synthesis coupled with selective molecular sieving). Excellent biocompatibility and purity are found in PEGs with precisely defined length and oxyethylene unit count. PEG chain length has an impact on PEGylated liposome transfection effectiveness, but so does the lipid hydrophobic domain's nature on cellular uptake.

Rapidly diffusing short aliphatic derivatives from the liposomal surface lessens the prolonging impact. Furthermore, bases for PEGylated lipids can be used, such as steroids and lipopeptides.
When PEG containing lipids are incorporated during the formation of thin lipid films, PEG chains form on the two distinct inner and outer membranes of the lipid bilayer. The liposomal bilayer surface is the only thing that changes with the post-insertion method. The post-insertion technique only changes the outer liposomal bilayer surface [51, 52].

Post-insertion PEGylation

To achieve a significant amount of PEGylation (greater than 5% PEG), the post-insertion approach is more efficient [53]. The PEG derivative interacts with certain hydrophobic anchor or matrix lipids on the liposomal membrane’s external surface, where PEGylated conjugates are mostly located [54]. Due to an adequate ligand arrangement on the outer liposomal surface and a high degree of embedding under ideal circumstances, the execution of this strategy decreases non-specific interactions between ligands and liposomes [55]. The conventional drug loading approach is unaltered by this technique. Post-insertion technique is a promising method for liposomal system mediated gene transfer to cancer cells [56, 57].

Significance of PEGylation

For more than 25 y, PEGylation is one of the most important approaches, has been used therapeutically to minimize the immunogenicity of nano-therapeutics and improve the pharmacokinetic (PK) properties of drugs [58]. Many pharmaceutical products on the market today utilize PEGylated therapeutics, and new PEGylated therapeutics are being developed for longer drug half-lives [59]. Systems for delivering PEGylated drugs are crucial in the treatment of cancer. The plasma half-life of several therapeutics, including proteins, enzymes, small molecule drugs, nanoparticles, and liposomes, can be increased by PEGylation. It could be executed by blocking opsonins from removing them from the bloodstream, increasing their therapeutic index.

The surface modification of nanocarriers using PEG with various chain lengths, shapes, densities and molecular weights demonstrated a tremendous potential for the creation of enhanced drug delivery techniques for the treatment of cancer [60]. Protein conjugates that have been PEGylated are often employed in therapeutics. Covalent bonds between poly (ethylene glycol) and most proteins that the Food and Drug Administration (FDA) has approved for conjugation (PEG). These PEGylated drugs showed longer blood circulation duration, requiring fewer doses which improve patient compliance [61]. In pharmaceutical and biological applications, PEG improves protein stability, therapeutic efficacy, and shelf life for bioactive compounds; nevertheless, the optimal position of PEG attachment into proteins is still not clearly revealed. More research is needed for clinical validation since the researchers found that PEGylation efficiency, protein stability and protein function vary depending on the PEGylation location [62, 63].

Characterization parameters of liposomes

Liposomes are generally possessing low intrinsic toxicity and there are various characterization studies for the liposomes are as follows: (fig. 6).

**Size distribution**

Photon correlation spectroscopy was used to determine the liposome size distribution which ensures the stealth liposomes identical size (mean liposome size of 100 nm) [64, 65].

**Zeta potential**

Electrophoretic mobility measured at a 90° angle was used to determine the Zeta potential. The 3000Hs zetasizer equipment was used to do the measurements in triplicate and the samples are diluted with suitable solvent system [66].

**Lipid quantification and chemical stability**

The amount, purity of cholesterol and the concentration of phospholipids were determined using High Performance Liquid Chromatography (HPLC) or evaluated using cholesterol oxidase enzymatically, and the purity of phospholipids as raw materials and the degree of their hydrolysis throughout various liposome synthesis were evaluated by Thin Layer Chromatography (TLC).

**Drug quantification**

Drug concentration of the liposomes is usually estimated using a spectrophotometric technique. The drug amount is validated by HPLC throughout the development and storage of the liposomes, the drug’s purity and level of degradation is evaluated using a combination of HPLC.

**Liposome stability**

Stealth liposomes stability is studied by dilution of the formulation with 10 times either with mouse plasma pH 7.4 or 0.9% NaCl, pH 6.5, and incubated for 30 min at 37 °C. The drug release from the liposome is separated and evaluated by ultracentrifugation at 150,000g for 60 min at 10 °C, followed by atomic absorption spectrometry in a graphite furnace [67].
Drug release determination

Using a dialysis method, in vitro drug release assessments of drugs from both naked liposomes and stealth liposomes can be performed. To remove any free drugs, bare liposomal dispersion is first predialyzed in buffered saline using dialysis tubing in a dialysis tube resembling a blank marine plasma tube. A 2 ml of stealth liposomal solution and 2 ml of blank marine plasma is mixed. Two beakers, each holding 50 ml of HBS are used to hold naked and stealth liposome loaded dialysis tubing. A water bath is used to incubate the beakers at 37 °C. Aliquots of the samples removed carefully out of the beakers at time intervals of 0 min, 5 min, 15 min, 30 min, 1 hour, 4 h, 6 h, 10 h, 24 h, and 48 h and replaced with an equal amount of HBS. Both the fluoro-spectrophotometry method and the HPLC method can be used to determine the drug concentrations based on the loaded drug. The percentage release rate can be calculated using the formula below. The amount of medication released, or the release medium was measured as W (g), while the total amount of drug added to the liposomes is measured as W (g). The formula for the drug’s release rate is (Win/Wt) × 100% [68].

Level of free drug

The two techniques used for this study are small gel exclusion chromatography and selective drug adsorption on Dowex cation exchangers, which is carried out in either small glass columns or polycarbonate pipette tips (0.1-1.0 ml).

Applications of pegylated liposomes in cancer and other diseases

To prolong circulation periods and prevent interactions with other components as well as avoid reticuloendothelial system clearance stealth liposomal formulations are widely used for in vivo administration of chemotherapy drugs [69, 70]. To facilitate drug transport to the targeted site, the surface of nanoparticles is conjugated by ligands for site specific delivery. Because malignant cells are more vascularized than healthy cells, stealth liposomes have the capacity to gather in cancer tissue. However, it has been discovered that functionalizing or conjugating Stealth liposomes with different ligands improves active targeting of cancers.

A study was conducted to find out whether quercetin could be delivered to HeLa and cervical cancer cells using stealth liposomes [71] and it demonstrated improved particle stability and 44 fold increased flavonoid absorption. To prolong the drug’s biological half-life and enhance systemic circulation, trans-resveratrol loaded DSPE-PEG 2000 was tested on glioma cells. It was demonstrated that the developed stealth formulations increased the drug’s plasma half-life by 18 times and improved cerebral distribution by 9 times when compared to drug solution [72]. In a different investigation, cholesteryl liposomes with folate were specifically developed to target HeLa cells and release doxorubicin [73]. Intravenous drug loaded liposomes improved cell interaction and cytotoxicity in cancer cells without having a deleterious impact on the heart or kidneys.

Liposomes functionalization with transferrin (TF)

Most of the cancers have high levels of transferrin receptors (TF) and using modified liposomes can enhance the absorption of nanoparticles by the cancer cells that form tumours. The results point to functionalizing TF for site specific anticancer drug delivery via Stealth liposomes, carbon quantum dots, or polymeric surfaces. The transferrin receptor induces endocytosis due to the serum glycoprotein TF, which transports ferric ions when internalized. After adhering to the cell surface, TF internalizes complexes quickly via covered pits as a ligand receptor, entering to the cellular compartment where the anticancer drug delivery occurs [74].

Stealth liposomes were combined with TF for the active targeting of sirolimus (SRM) in the treatment of breast cancer. When sirolimus loaded TF-DPPC stealth liposomes was compared to TF-DSPC-stealth, the later demonstrated greater cell cytotoxicity and less cell viability, demonstrating an antiproliferative effect. Compared to free drug and non-conjugated stealth nanoparticles, sirolimus loaded liposomes had a greater anticancer impact for TF stealth nanoparticles and significantly suppressed tumor formation. The results demonstrate the potential of sirolimus encapsulated TF stealth liposomes as a drug delivery system for the treatment of breast cancer and tumour active targeting.

Liposomes as theranostics and cancer therapeutics

Liposomes that are loaded with chemotherapy drugs are now an effective delivery system in treatment of cancer. Cancer Multidrug Resistance (MDR), a condition where the disease becomes resistant to anticancer drugs, is the greatest barrier to obtaining a potential effective cure. The chemotherapeutic drugs encapsulated in nanocarriers like liposomes are able to bypass many MDR causing pathways, enhancing the treatment efficacy against multidrug resistant malignancies. Pegylated liposomes can also be utilized to deliver cytotoxic drugs to cancerous cells. USA and Europe authorized the Pegylated Liposomal Doxorubicin (PLD) (DOXIL/Caelyx) which is the first and only stealth liposome for treating Kaposi’s sarcoma and recurrent ovarian cancer. Presently, multiple myeloma, breast cancer, and recurrent high grade glioma are among the cancers that can be treated with DOXIL/Caelyx. Currently being investigated (pactixalet or docetaxel) are the anticancer effects of PLD in conjunction with vinorebline, taxanes, and temozolomide (Temodar® Schering-Plough, Kenilworth, NJ, USA). In a molar ratio of 55:40:5, DSPC, CHOL, and mPEG-DSPE (molecular weight 2000) make up the rigid bilayer of PLD. Doxorubicin may be integrated into liposomes with a mean diameter of 85 nm at a dose of 2 mg/ml. In contrast, the plasma half-lives of the free drug are 0.2 h, those of myocet and daunoxome are 2-3 h, and those of the free drug are 5 h, and the pharmacokinetics is rather sluggish. Half-lives for plasma elimination range between 1.5 and 4.5 h and follow a bi-exponential curve (median values).

The distribution volume is small, and the plasma clearance is clearly slow (0.11/h), with almost all of the drug identified in the plasma after PLD injection being liposome encapsulated when compared to a similar dose of traditional doxorubicin, PLD’s pharmacokinetic includes considerably lower cardiotoxicity, myelosuppression, alopecia, and nausea 5-CDK602 (Alza Corporation), A Pegylated stealth liposome loaded with CKD-602, a semisynthetic analogue of campothecin, shows low toxicity and exceptional efficacy. At doses of 0.5 mg/m2, S-CBD602 has a plasma AUC 50 times greater than non-pegylated CKD-602. In addition to soyPC, CHOL, mPEG2000-DSPE, dipalmitoylphosphatidyl glycerol (DPPG), and soy phosphatidyl choline, lipoplatin is a unique liposomal cisplatin formulation. Depending on the dosage, it’s stated half-life ranges from 60 to 117 h. According to the study, lipoplatin exhibits none of the adverse effects that cisplatin does up to a dosage of 125 mg/m2 every 14 d [75].

The Doxil®, which comprises 100 nm doxorubicin loaded Pegylated liposomes with mPEG2000 as a surface coating, numerous cancers, including ovarian, breast, and AIDS related tumours linked to Kaposi’s sarcoma, have been effectively treated with it [76]. Rhenium-186 (186Re) labelled Doxil is developed from Doxil by remotely adding 186Re-BMEDA [N,N-bis (2-mercaptopethyl)-N,N-diethyl ethylene diamine] through the already-present ammonium sulphate gradient. BMEDA is a weak base that may actively load into the Doxil core and chelate 186Re. The 90-hour half-life of the dual emitting radionuclide 186Re makes it appropriate for single photon emission computed tomography imaging as well as cancer treatment (SPECT). Relabeled Doxil outperformed Doxil by itself in a xenograft model of head and neck squamous cell cancer. These novel theranostic stealth liposomes allowed for 120 hour real time and quantitative drug delivery tracking, which showed significant tumour development from 4 to 120 h [1-2% injected dosage (ID)/g tissue] and delayed blood clearance with a half-life of 24 h. By active loading technique, 186Re could be maintained inside the aequous core of Doxil resulting in greater labelling stability than the traditional method, which only transfers the radionuclide through the lipid bilayer of the liposomal surface via a lipid containing a metal chelating group. Recent developments in the treatment of brain cancer include the formulations (2B3 and G-Technology®) that are based on glutathione Pegylated liposomal doxorubicin. Based on Doxil®, it has a glutathione layer added to the surface to improve the
distribution of drug across the blood brain barrier (BBB) without compromising safety. Two separate experiments utilizing 283-101 liposomes revealed a substantial reduction in brain tumour growth factor as indicated by the level of bioluminescence [77]. When treated once a week at a dose of 5 mg/kg, 283-101 showed a more effective antitumour effect than saline, and PEGylated liposomal doxorubicin. Only 2 out of 9 rats receiving 283-101 indicated complete cancer remission, hence there was a minimal tumour decrease observed.

The growth of brain tumour was significantly inhibited by 283-101 injections given twice weekly at a dose of 5 mg/kg, in contrast to doxorubicin based PEGylated liposomes and saline, and a complete suppression was observed in just one rat given the drug. Additionally, 283-101 given twice weekly significantly extended average survival time by 38.5% and 16.1%, respectively, over saline and PEGylated liposomal doxorubicin [78]. The findings demonstrated that glutathione PEGylated liposomal doxorubicin enhanced the drug’s effectiveness in transporting the targeting ligands directly to brain tissue, potentially resulting in the treatment of brain cancer. The FDA has approved LipoDox®, a different PEGylated liposomal version of DOX produced by Sun Pharma in 2012 [79]. Onivyde®, a different irinotecan containing PEGylated liposome, shows an extended antitumor impact [80].

The FDA authorized OnivydeTM, which also contains the anticancer drug irinotecan, to treat metastatic adenocarcinoma Distearoyl phosphatidyl choline, cholesterol, and distearoylphosphatidyl ethanolamine are all present in OnivydeTM in the amounts of 3:2:0.015. The co-delivery of molecules of ribonuclease interference (RNAi) towards thymidylate synthase complexed to PEGylated based liposomes [PEGylated thymidylate synthase complexed with cationic liposomes[TS shRNA-lipoplex]] and oxalaplatin (1-0HP) containing liposomes for the treatment of solid tumors is a well-researched example of combination therapy. This combined therapy is a potential way to improve the therapeutic effect of 1-0HP by overcoming the immune response caused by the RNAi molecule by precisely delivering TS-shRNA to cancer tissues. In contrast to single therapies using 1-0HP-based liposomes or TS-shRNA alone, TS-shRNA significantly inhibits tumor development by fundamentally preventing cell proliferation through gene silencing [81].

Other clinical uses for PEGylated liposomes include the clinical diagnostic application of postinfection tomography (PET) imaging and the use of internal cancer radiotherapy. PEGylated 177Lu loaded liposomes [82]. Patients with brain metastases are the primary target for the PEGylated liposomal Dox formulation 283-101 [83]. The blood brain barrier (BBB), which prevents the entry of xenobiotics and endogenous substances, makes it difficult to target brain cancers. G-technology, based on the biology of human safe receptors, was the area of research that made 283-101 possible. It is the most adaptable technique for encapsulating different molecules, including drugs of both high and low molecular weights, hydrophilic and lipophilic chemicals, and other substances [84].

The transport of the encapsulated moiety across the blood brain barrier is facilitated by glutathione PeOylation, was employed in the formulation of this product S-CKD602, a potent topoisomerase I inhibitor (CKD-602) containing PEGylated liposomal formulation manufactured by the Alza Company [85]. The formulation’s extended circulation property is associated with increase in area under curve (AUC). In comparison to unencapsulated form, the AUC of the semi synthetic camptothecin analogue CKD-602 was 50 times greater in liposomes [86]. The mPEG linked phospholipids on the outside of the lipid bilayer that composes the camptothecin analogue CKD-602 stealth liposomes. mPEG lipids provide liposomes the advantages of extended plasma circulation period and enhanced administration of drugs to tumours over conventional liposomes [87].

In preclinical investigations using these liposomes, there is a 3-10 fold improvement in therapeutic index over the non liposomal formulation. When compared to muscle tissue, fat tissue exhibits a distinctive characteristic of enhanced dispersion that vary depending on the patient’s body composition, according to the phase II trial study on S-CKD602 [88]. In the aequous core of sterically stabilized liposomes, cisplatin is present in the stealth liposome formulation SPI-0770 (totally hydrogenated soy HSPC, cholesterol, and DSPE-PEG). These compounds behave stealthily because of their apparent half-lives of 60 to 100 h.

According to investigations using zoledronic acid (ZOL) encapsulating PEGylated liposomes (LipoZOL) on a laboratory animal model of neuropathic pain, two intravenous doses of 10 g of ZOL administered at days 2 and 4 upon an injury, either free or combined with liposomes, significantly decreased mechanical hypersensitivity at days 3 and 7 after nerve injury. Free ZOL, however, made no noticeable difference to the mechanical barrier. Seven days after spared nerve injury (SNI), glial fibrillary acidic protein (GFAP)-labeled astrocytes revealed as hypertrophic, cells that were activated in the ipsilateral dorsal horn, according to an immunohistochemical investigation of the spinal cord.

LipoZOL caused a protective phenotype, which significantly changed astrocyte shape without changing the total number of cells. Interleukin 10 was also found within the spinal cord astrocytes of the LipoZOL treated rats. By monitoring the biodistribution of fluorocently labelled liposomes, ZOL’s transit to the Central Nervous System (CNS) was exhibited. However, a fluorescence spike in the brain and spinal cord only emerged in neuropathic mice at the 30 min and 1 hour period. Notably, the liver and kidney of both the normal and neuropathic animal groups accumulated liposomes. The results indicate that ZOL, if administered with a delivery mechanism that can pass through the altered BBB, may provide a unique pathway for the treatment of neuropathic pain [89].

Palbociclib (PAB) was encapsulated in stealth liposomes (LPS) with a vesicle size of less than 100 nm to target cyclin-dependent kinase (CDK4 and CDK6) in triple negative breast cancer. First order, biphasic release kinetics can be observed in LPS-PAB. LPS-PAB also exhibits a lower half-maximal inhibitory concentration (IC50) value (1.99 M) compared to PAB alone (3.24 M). The proposed nanoliposomes were dyed with fluorescein isothiocyanate (FITC) to enable fast cellular uptake. Notably, stealth LPS-PAB has shown a 1.75 fold reduced hemolytic potential than PAB plain medicine at a dose of 100 g/ml. The PK results revealed 2.5 fold higher Cmax, 1.45 fold higher AUC0-14, 1.8 fold higher half-life, and 1.3 fold higher MRT when compared to PAB suspension given orally [90]. The stealth liposomes developed with PEG5000 possessed a greater encapsulation efficiency (83 0.4%) and a delayed rate of drug release (32.2% in 9 h) when compared to stealth liposomes developed with PEG2000 (79.0 4.53% respectively) and conventional liposomes (64.8 0.8% and 52.4%) respectively [91].

Liposomal delivery for vaccines

It has been proved that genetic vaccinations with antigens from bacteria, viruses, and cancer have the potential to maintain cellular and humoral immunity. Clinical trials have shown the effectiveness of liposome based vaccines, and additional human trials are currently underway. Hepatitis A virus that has been rendered inactive and is anchored to a phospholipid bilayer can be discovered in Epxal, a liposomal based hepatitis A vaccine [92, 93]. In healthy human volunteers, the liposome based malaria vaccine has been shown to increase levels of anti malarial antibody [94]. It is being studied whether the liposomal mycobacterium tuberculosis vaccine enhances T cell mediated immunity in human subjects [95].

Liposomes in transfection

Stealth liposome formulation makes for the ideal cationic transfecting vectors. By encoding the gene encoding a therapeutic protein in liposomal vesicles, allowing DNA plasmid to condense into a highly organized structure, the gene can be protected against DNA breakdown. The structure of the gene delivery system must bypass the biological membranes and permit endosomal exit to prevent DNA degradation in the liposomal compartment. For the delivery of genes, numerous cationic liposomal formulations have been tested. The therapeutic application of cationic liposomes is subject to several limitations, such as rapid clearance, large particle size,
immunostimulation, and complement activation. To skirt these restrictions, PEGylated cationic liposomes are used to increase in vivo circulation time, reduce immunostimulation, and activate complement less. Commercially available cationic liposomes for gene transfection include Lofectamine 2000. Curcumin liposomes containing signal mediator and activator of transcription 3 small interfering RNA (STAT3 si-RNA) are produced using the Bangham method to treat skin cancer. Liposomes inhibit the development of B16F10 melanoma cells better than free STAT3 si-RNA and free curcumin. For the treatment of many tumors and genetic disorders, the clustered regularly interspaced short palindromic repeats (CRISPR or Cas9 gene) can be delivered via liposomes [96].

Stealth liposomes in diagnostic imaging

In contrast methods like gamma scintillation, magnetic resonance imaging (MRI), computed tomography imaging (CTG), and sonography, stealth liposomes are used as vesicles to carry different types of compounds in bilayer or in the aqueous compartment. The ability of stealth liposomes to integrate several contrast moieties, deliver the agent accurately to the target area, and increase the contrast signal to the diagnostic agent are only a few advantages of employing stealth liposomes in diagnostic imaging (Te, Mn, Gd). A soluble chelating compound that will be enclosed in the aqueous core of vesicle may be utilized for complex metals. Gadolinium containing PEGylated liposomes that have been stericly stabilized serve as incredibly potent contrast agents in magnetic resonance imaging [92, 97].

Stealth liposomes in targeted drug delivery

Targeted stealth liposomes offer several advantages over individual drugs targeted by polymers or antibodies. One of the most recent developments is the dramatic increase in the amount of drug that can be delivered to the target. Additional ligand molecules exposed on the liposome surface may also increase ligand avidity and absorption. Due to the drug molecules tendency to disseminate into nearby tumor cells, immune liposomes also have a "bystander killing effect" [92]. The first human monoclonal antibody for metastatic breast cancer was the anti-HER2 antibody known as trastuzumab [98]. To specifically target doxorubicin, daunorubicin, and cisplatin to the cancer cells, folic acid containing liposomes are used [99]. Liposomes with a transferrin ligand attached are used to deliver anticancer medications, proteins, and genes to cancer cells [100]. Stealth liposomes containing haperiodal are being used to target specific genes in breast cancer cells [101]. Target delivery is accomplished using stealth liposomes with 13 L-peptides [102].

PEGylated liposomes-enhanced permeability and retention (EPR) effect

The reticuloendothelial system (RES) interacts significantly with conventional approaches in cancer therapy. The development of a delivery system or nanocarrier that can evade the body’s phagocytosis defense mechanisms. PEGylated liposome is one of the methods to prolong the duration of blood circulation. Cancer cells have increased leakiness or permeability. This strategy is called passive targeting. Moreover, macromolecule buildup is also driven on by restricted lymphatic outflow. This phenomenon is known as the enhanced permeability and retention (EPR) effect [103, 104]. To provide appropriate oxygen and nutrients supply that sustains tumour development, neovascularization is crucial for tumour progression.

A tumor’s abnormal vascular network is formed by an unbalanced angiogenic regulatory system and is marked by dilated, leaky blood vessels, poor lymphatic drainage, and other characteristics. A long circulation period for nano sized drug carriers is made possible by the distinct pathophysiolegy characteristics of tumour vasculature. Rather than normal tissues, PEGylated liposomes were specifically retained and released into malignant tissues. Hence, it is anticipated that utilizing PEGylated liposomes containing anticancer drugs will result in less drug toxicity [105, 106].

Maeda and his coworkers gave the initial description of EPR [107]. The primary mechanism for the selective deposition of nanomedicines in tumour site is recognized to be the EPR effect [108]. Using the EPR effect, PEGylated Liposomes, a form of nanocarrier treatment, are used as a drug delivery method to target malignant cells. It has been demonstrated that PEG surface modification decreases liposome absorption by MPS substantially, increases the concentration of PEGylated liposomes in tumours, and increases the half-life of liposomes. PEGylated liposome upon passive accumulation in solid tumours doesn’t disperse evenly due to the wide range of EPR effects found in tumour tissues [109].

On the contrary, extravasation and tumour accumulation of PEGylated liposomes are significantly influenced by tumour factors such as tumour size, type of malignancy, and quantity of tumour vasculature [110]. Doxil® PEGylated Doxorubicin Liposomes, which exhibited stealth characteristics were proven to enhance the serum half-life of their loaded active ingredient, are a perfect example. Since glutaminolysis, a specific metabolic pathway for tumour cells, induces a significantly greater quantity of ammonia in tumour tissues, it was claimed that doxorubicin was exclusively released in the interstitial fluid of the tumour. After the doxorubicin has been released from the liposomes, the cancer cells absorb it and get damaged.

Pharmacokinetic considerations of PEGylated liposomes

The phagocytosis Reticuloendothelial System (RES) components often eliminate the nanocarrier based drugs from the blood, such as liposomes (both PEGylated and Non-PEGylated Liposomes). RES is mostly found in the spleen, bone marrow, and liver (hepatic kuffer cells), which also contain monocytes, macrophages, and dendritic cells. Hence, elements that affect RES activity might alter the rate of clearance, toxicity, and pharmacokinetics of liposomal drugs [111]. With the intervention of the immune system, particularly RES macrophages, nanomedicine and liposomes are eliminated from the circulation system after systemic delivery [112]. Hence, the distinctive pharmacokinetics of nanocarrier systems affect the drug delivery. As a result, the unique pharmacokinetics of nanocarrier systems has an impact on medication delivery.

PEGylated liposomes enhanced tumour delivery by modifying the pharmacokinetic and distribution properties of the encapsulated drugs upon intravenous administration. Chemotherapy is identified as having increased anticancer efficacy and reduced toxicity as compared to conventional cytotoxic drugs because of its stagnant blood vessel leakage and tendency for accumulation in tumour tissues. Nanocarrier pharmaceuticals should be developed with the ability to withstand these clearance pathways and inhibit complement activation in order to prolong the half-life of anticancer drugs in the blood stream [113, 114].

Regulatory considerations and clinical trials

The Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved nearly 100 nanomedicines while numerous nanomedicines are currently undergoing clinical trials, during the past several years [115-117]. The FDA, EMA, Ministry of Health, Labour, Welfare Japan (MHLW), and Chinese National Medical Products Administration (NMPA) released several guidelines about nanomaterials and nanoparicles to share the regulatory network's experience in the scientific evaluation of nanomedicines in response to the tremendous growth in nanomedicine applications. These recommendations involve several different nanoparticles delivery systems viz., liposomes, nanocacoiloid products (iron based), block copolymer micelles, and nano products containing small interfering RNA (siRNA). Owing to the very extensive dosage form and the relatively high number of liposomes approved in market and clinical studies, all four regulatory agencies collaborated to develop the liposome regulatory guidance. The overview of the guidelines is depicted in (fig. 7).

Based on these guidelines, we emphasize the significance of developing a broad knowledge base to better comprehend any risk to a product’s physicochemical and biological characteristics that is encountered during manufacturing, analysis, and material control. Early pharmaceutical research and development can provide knowledge that can be updated over time by future production and associated control strategies. Lower risk results emerge from an understanding of the connections between Key Material Attribute (CMA), Critical Process Parameters (CPP), physicochemical characteristics, and in vivo performance of liposomes [118].
additives, particularly those used in lipids, are crucial to the effectiveness of liposomal products. A slight modification to the lipid components might cause a change in the drug’s pharmacokinetics or pharmacodynamics, which could result in significant toxicity. The FDA regulation insists on guidelines regarding the requirements for lipid supply (extraction or synthesis), lipid characteristic, specification, and stability are necessary for lipid control. Sterilization is regarded as a challenging process in the manufacture of liposomes since most liposomal substances are designed to be administered via parenteral routes.

Sterile filtering using a 0.22 m membrane is extensively used in the pharmaceutical industrial sector. Nevertheless, issues such as membrane blockage, impaired liposome integrity, and insufficient retention of tiny bacteria may emerge [119]. Hence, for batch consistency and sterility assurance of liposome products, the promising sterilization method and the process validation are essential. While manufacturing liposome preparatons, the rate at which the nanoparticle payload leaks may be significantly quicker than anticipated and the in vivo and in vitro studies must be taken into consideration [120]. The Center for Drug Evaluation (CDE), in a recently published guideline for nonclinical pharmacokinetics of nanomedicine known as NMPA, recommends in vivo research on vehicles other than cargos [121]. The most useful technique for tracking the movement of vehicles in real time is fluorescent labelling.

Thus, it is crucial to distinguish fluorescent chemicals released from nanoparticles in free form apart from intact carriers [122]. Aggregation Caused Quenching (ACQ) is a promising method for the removal of free probe interference due to the environment responsiveness properties, even if the phenomenon was negative in bio imaging [123-125]. Due to "π-π stacking," the near infrared fluorescence that the ACQ probes exhibit when placed in carrier matrix (usually molecularly dispersed) completely disappears as soon as they are released into the aqueous environment. Hence, the undamaged automobiles are identified by the fluorescence. With the ACQ probes, several nanoparticles' in vivo fates have been studied, including those administered via various routes (such as oral, intravenous, transdermal, nasal, and ocular), micelles, nanoemulsions, and nanocrystals [126-130].

CONCLUSIONS
Stealth liposomes that actively target tumour cells have long become the topic of extensive study. Even so, due to the steric stability provided by the mPEG group, the liposome-entrapped DNA seems to be challenging for cells to ingest. Possible remedies and several proposals have addressed the delivery conundrum. One such technology that employs mPEG groups that may be removed from the liposome surface during extravasations and penetration into malignancies is the polymer modified liposomes (PolyVERSE liposome system). The idea of using stealth liposomes to deliver anti-inflammatory medications to inflamed areas seems appealing. Clinical research demonstrates that stealth liposomes bearing radioactive tracers passively target infection and inflammatory areas in a way like how Doxil targets to tumour site. To date, liposomal delivery systems with modifications have been researched for many clinical dimensions. Liposomes are one of the most preferred delivery approaches in cancer and other diseases. More studies are ongoing in understanding the pharmacokinetics of the PEGylated stealth liposomes, which is one of the promising delivery systems in combatting various types of cancer.

FUNDING
Nil

AUTHORS CONTRIBUTIONS
All authors have contributed equally

CONFLICT OF INTERESTS
Declared none

REFERENCES


route
Xia
nanoparticles: the crucial role of discriminating nanoparticles
Hu
Bulbake
Gadekar
P10.1016/j.jconrel.2015.11.002
Nakamura
appropriate target?
78
protein
nanoparticles: critical issues in pharmacokinetics, opsonization and
liposomal doxorubicin
with theranostic and radiotherapeutic potential using micro
10.1007/s00259-015-3272-6; PMID 26646780.
10. La-Beck NM, Tibbioni BA, Gabizon A, Schmeeda A, Amantea M,
Gehrig PA. Factors affecting the pharmacokinetics of pegylated
10. Moghim SM, Sabeni I. Stealth liposomes and long circulating
nanoparticles critical issues in pharmacokinetics, osmoporation and
10. Kobayashi H, Watanabe R, Choyke PL. Improving conventional
enhanced permeability and retention (EPR) effects; what is the
appropriate target? Theranostics. 2013;3(1):89-91. doi:
10.7150/thno.7193; PMID 24396516.
H. Intra-tumor distribution of pegylated liposome upon repeated
injection: no possession by prior dose. J Control Release. 2015
10. Poornima K, Puri A, Gupta A. Understanding the stealth
Nanomedicines accessible in the market for clinical interventions.
J Control Release. 2021 Feb 10;330:372-97. doi:
10. Q8(R2) 2019. Pharmaceutical Development. Available from:
https://www.ich.org/page-quality-guidelines. [Last accessed on
20 Jun 2021]
methods of liposomes: drawbacks of conventional methods and
perspectives. J Pharm. 2021 Mar 15;59:120271. doi:
10. He H, Jiang S, Xie Y, Lu Y, Qi J, Dong X. Reassessment of long
circulation via monitoring of integral polymeric nanoparticles
justifies a more accurate understanding. Nanoscale Horiz. 2018;3(4):
397-407. doi:10.1039/b800100g; PMID 32241427.
10. Guideline for the nonclinical pharmacokinetics of
Available from:
http://www.cde.org.cn/zdyy.do?method=largePageandId=1be98aec28f7a72.[Last accessed on 25 Jun 2021]
10. Hu X, Dong X, Lu Y, Qi J, Zhao W, Wu W. Bioimaging of
nanoparticles: the crucial role of discriminating nanoparticles
bioimaging of drug nanocarriers: turning aggregation-caused
quenching into a useful tool Adv Drug Deliv Rev. 2019 Mar
15;143:206-25. doi:10.1016/j.addr.2019.05.009; PMID
31158405.
10. Xia F, Chen Z, Zhu Q, Qi J, Dong X, Zhao W. Gastrointestinal
lipolysis and trans-epithelial transport of SMEDDS via oral
route. Acta Pharm Sin B. 2021 Apr 1;11(4):1010-20. doi:
10.1016/j.japbsb.2021.03.006; PMID 33996413.
of orally administered mPEG-PDLLA polymeric micelles. J Control
10. Li Y, Wang C, Zong S, Qi J, Dong X, Zhao W. The trigeminal
pathway dominates the nose-to-brain transportation of intact
polymeric nanoparticles: evidence from aggregation-caused
quenching probes: size-dependent translocation via oral
delivery. Adv Healthc Mater. 2018 Nov 7(22):e1800711. doi:
10.1002/adhm.201800711; PMID 30345713.
10. Kumar P, Huo P, Liu B. Formulation strategies for folate-
targeted liposomes and their biomedical applications.
10. Kumar P, Huo P, Liu B. Formulation strategies for folate-
targeted liposomes and their biomedical applications.
approach of targeted drug delivery in cancer therapy. Int J
10. Khan YV, Subarna V. Liposomes containing phytochemicals for
cancer treatment-an up to date review. Biomed Nanotechnol. 2019
30845193.
10. He H, Xie Y, Lv Y, Qi J, Dong X, Zhao W. Bioimaging of intact
polyacrolactone nanoparticles using aggregation-caused
quenching probes: size-dependent translocation via oral
delivery. Adv Healthc Mater. 2018 Nov 7(22):e1800711. doi:
10.1002/adhm.201800711; PMID 30345713.
10. Kusuma P, Vinod K, Damini VKK. Somes: a review on
composition, formulation methods and evaluations of different
types of “somes” drug delivery system. Int J App Pharm.